Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Alexandre

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Journal of Clinical Pharmacology|November 18, 2014
Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?)A Thomas-Schoemann, B Blanchet, P Boudou-Rouquette, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2016
Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patientsE Carton, G Noe, O Huillard, et al.
Investigational New Drugs|October 26, 2014
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patientsC Narjoz, A Cessot, A Thomas-Schoemann, et al.
British Journal of Clinical Pharmacology|February 1, 2019
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumoursR Cohen, L H Preta, V Joste, et al.
Gynecologic Oncology|October 15, 2021
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 studyF Gernier, A Gompel, C Rousset-Jablonski, et al.
Gynecologic Oncology|November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12F Heitz, P Harter, E Åvall-Lundqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancerA Poveda, J M Del Campo, I Ray-Coquard, et al.
ESMO Open|April 12, 2025
Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe studyS Quesada, A Puszkiel, A Jouinot, et al.
ESMO Open|July 29, 2021
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgeryP Pautier, A Floquet, C Chevreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2019
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I studyF Joly, D Ahmed-Lecheheb, E Kalbacher, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Journal of Clinical Pharmacology|November 18, 2014
Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?)A Thomas-Schoemann, B Blanchet, P Boudou-Rouquette, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2016
Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patientsE Carton, G Noe, O Huillard, et al.
Investigational New Drugs|October 26, 2014
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patientsC Narjoz, A Cessot, A Thomas-Schoemann, et al.
British Journal of Clinical Pharmacology|February 1, 2019
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumoursR Cohen, L H Preta, V Joste, et al.
Gynecologic Oncology|October 15, 2021
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 studyF Gernier, A Gompel, C Rousset-Jablonski, et al.
Gynecologic Oncology|November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12F Heitz, P Harter, E Åvall-Lundqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancerA Poveda, J M Del Campo, I Ray-Coquard, et al.
ESMO Open|April 12, 2025
Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe studyS Quesada, A Puszkiel, A Jouinot, et al.
ESMO Open|July 29, 2021
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgeryP Pautier, A Floquet, C Chevreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2019
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I studyF Joly, D Ahmed-Lecheheb, E Kalbacher, et al.
Pageof 11